Evaluation of the efficacy of switching from a xanthine oxidase inhibitor (febuxostat) to a selective urate reabsorption inhibitor (dotinurad) in patients with hyperuricemia and chronic kidney disease (CKD).

Switching from febuxostat to dotinurad in patients with chronic kidney disease and hyperuricemia: a single-center, non-randomized study - Switching from febuxostat to dotinurad in patients with chronic kidney disease and hyperuricemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060295

Enrollment

Registered

2026-01-08

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia with chronic kidney disease

Interventions

Patients were switched from the xanthine oxidase inhibitor febuxostat to the selective urate reabsorption inhibitor dotinurad, with the dosage adjusted according to the following conversion protocol:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients aged 20 years or older with hyperuricemia and stage G2-G4 chronic kidney disease (CKD) who are not undergoing dialysis. (2) Patients currently receiving the xanthine oxidase inhibitor febuxostat.

Exclusion criteria

Exclusion criteria: (1) Presence of active gouty arthritis. (2) Any other conditions that the attending physician considers unsuitable for study participation

Design outcomes

Primary

Measure	Time frame
Patients were switched from the xanthine oxidase inhibitor febuxostat to the selective urate reabsorption inhibitor dotinurad. We compared renal function parameters (serum creatinine, cystatin C, and eGFR), serum uric acid levels, urinary protein, and the fractional excretion of uric acid (FEUA) between baseline (pre-switch) and three months after the switch.	—

Countries

Japan

Contacts

Public ContactTaisuke Irifuku

NHO Higashihiroshima Medical Center Department of Nephrology

t.irifuku@gmail.com082-423-2176

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026